- Home
- AMBC vs YMAB Comparison
AMBC vs YMAB Comparison
Compare AMBC & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBC
- YMAB
- Stock Information
- Founded
- AMBC 1971
- YMAB 2015
- Country
- AMBC United States
- YMAB United States
- Employees
- AMBC N/A
- YMAB N/A
- Industry
- AMBC Property-Casualty Insurers
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AMBC Finance
- YMAB Health Care
- Exchange
- AMBC Nasdaq
- YMAB Nasdaq
- Market Cap
- AMBC 411.3M
- YMAB 386.7M
- IPO Year
- AMBC 1991
- YMAB 2018
- Fundamental
- Price
- AMBC $8.68
- YMAB $8.61
- Analyst Decision
- AMBC Strong Buy
- YMAB Buy
- Analyst Count
- AMBC 2
- YMAB 10
- Target Price
- AMBC $12.50
- YMAB $13.91
- AVG Volume (30 Days)
- AMBC 578.9K
- YMAB 842.3K
- Earning Date
- AMBC 11-11-2025
- YMAB 11-07-2025
- Dividend Yield
- AMBC N/A
- YMAB N/A
- EPS Growth
- AMBC N/A
- YMAB N/A
- EPS
- AMBC N/A
- YMAB N/A
- Revenue
- AMBC $257,879,000.00
- YMAB $85,385,000.00
- Revenue This Year
- AMBC N/A
- YMAB N/A
- Revenue Next Year
- AMBC $19.44
- YMAB $13.97
- P/E Ratio
- AMBC N/A
- YMAB N/A
- Revenue Growth
- AMBC 148.44
- YMAB N/A
- 52 Week Low
- AMBC $5.99
- YMAB $3.55
- 52 Week High
- AMBC $13.64
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- AMBC 51.60
- YMAB 81.21
- Support Level
- AMBC N/A
- YMAB $8.50
- Resistance Level
- AMBC $9.28
- YMAB $8.56
- Average True Range (ATR)
- AMBC 0.27
- YMAB 0.02
- MACD
- AMBC -0.38
- YMAB -0.13
- Stochastic Oscillator
- AMBC 92.73
- YMAB 112.50
About AMBC Ambac Financial Group Inc.
Ambac Financial Group Inc is a financial services holding company. It operates in two principal businesses segments: Insurance Distribution and Specialty Property & Casualty Insurance. Insurance Distribution segment includes Managing General Agents, Underwriters and other appointed and delegated underwriting businesses (collectively MGAs or MGA/Us), an insurance broker, and other distribution and underwriting businesses. Specialty Property & Casualty Insurance includes five carriers (collectively, Everspan). Key revenue is generated from Insurance Distribution.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.